More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.

Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.

$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.

Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.

The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.

Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.